Lifecore Biomedical (Lifecore Biomedical) Debt-to-EBITDA : -1.25 (As of May. 2023)

Lifecore Biomedical Debt-to-EBITDA Chart

Lifecore Biomedical Annual Data
	Trend	May14	May15	May16	May17	May18	May19	May20	May21	May22	May23
Debt-to-EBITDA		Get a 7-Day Free Trial					6.33	-30.88	-218.70	11.62	-3.41

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
Debt-to-EBITDA	Get a 7-Day Free Trial															24.48	-11.85	-7.53	-4.94	-1.25

Competitive Comparison of Lifecore Biomedical's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lifecore Biomedical's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Debt-to-EBITDA falls into.

Lifecore Biomedical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lifecore Biomedical's Debt-to-EBITDA for the fiscal year that ended in May. 2023 is calculated as

Lifecore Biomedical's annualized Debt-to-EBITDA for the quarter that ended in May. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (May. 2023) EBITDA data.

Lifecore Biomedical  (NAS:LFCR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Lifecore Biomedical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (Lifecore Biomedical) Business Description